Delivering comprehensive data capture for both general and vascular procedures, the Interventional Radiology module automatically documents Joint Commission on Accreditation of Healthcare Organizations and patient safety performance measures.
The Year Ended December 31, 2008 Year 2008 revenue growth came from $1.59 million of increased product revenues and $.23 million of increased research and grant revenues. The
Helix BioPharma, a Canada-based biopharmaceutical company, has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of topical interferon alpha-2b in patients
Australia-based biotechnology company Avexa has announced positive data from the ongoing Phase IIb clinical trial of apricitabine. After 96 weeks of treatment, no signature resistance to ATC has
The initial term of the agreement is five years totaling more than $3 million over the life of the agreement, assuming successful completion of the development of the
BioAlliance Pharma, a specialty pharmaceutical company, has received E6.4m in funding from OSEO, the French state innovation agency. The company will devote the funds to the development of
Dicerna’s pipeline of RNAi-targeted drugs and delivery systems is focused primarily in the therapeutic areas of oncology and metabolic diseases. In addition to these internal focus areas, Dicerna
Under the terms of the agreement, Globe Laboratories will license a new drug formulation for male sexual enhancement. The drug, which is in Phase I/II clinical trials, is
According to Arobella Medical, the wound therapy system uses a unique, dome-shaped curette tip to apply low-frequency, cavitational ultrasound to wounds. The combination of physical design and ultrasonic
Prior to joining Luminetx, Mr Kindberg served as divisional president for Durham, North Carolina-based Teleflex Medical, a medical device company. Mr Kindberg has also held numerous senior management
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.